Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9267

Generic Name


Brand Name



Central Monoamine-Depleting Agents.

Proposed Mechanism(S) of Action

Reversibly inhibits vesicular monoamine transporter type 2 (VMAT2), decreasing uptake of monoamines into synaptic vesicles and depletion of monoamine stores from nerve terminals.


Treatment of chorea associated with Huntington’s disease.

Off Label Use

No common off label use.

Side Effects


Prolonged QT syndrome, neuroleptic malignant syndrome, dysphagia, extrapyramidal event, akathisia.


Somnolence, fatigue, depression, anxiety, nausea, vomiting, bruising, irritability, dizziness, imbalance, Parkisonism/bradykinesia.

References and Readings

  1. Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66(3), 366–372.CrossRefGoogle Scholar
  2. Kenney, C., Hunter, C., & Jankovic, J. (2007). Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Movement Disorders, 22(2), 193–197.CrossRefGoogle Scholar
  3. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar

Additional Information

  1. Free Drug Online and PDA Software. www.epocrates.com
  2. Free Drug Online and PDA Software. www.medscape.com

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of PsychologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA